TY  - JOUR
AU  - Mansfield, A S
AU  - Każarnowicz, A
AU  - Karaseva, N
AU  - Sánchez, A
AU  - De Boer, R
AU  - Andric, Z
AU  - Reck, M
AU  - Atagi, S
AU  - Lee, J-S
AU  - Garassino, M
AU  - Liu, S V
AU  - Horn, L
AU  - Wen, X
AU  - Quach, C
AU  - Yu, W
AU  - Kabbinavar, F
AU  - Lam, S
AU  - Morris, S
AU  - Califano, R
PY  - 2019
DO  - 10.1016/j.annonc.2019.10.021
UR  - http://hdl.handle.net/10668/14971
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free and overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the IMpower133 study (NCT02763579). We have evaluated...
LA  - en
KW  - PD-L1
KW  - TECENTRIQ
KW  - atezolizumab
KW  - extensive-stage small-cell lung cancer
KW  - quality of life
KW  - safety
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - Etoposide
KW  - Humans
KW  - Lung Neoplasms
KW  - Patient Reported Outcome Measures
KW  - Quality of Life
TI  - Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
TY  - research article
VL  - 31
ER  -